Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07946068
PHASE1

Aleniglipron Renal Impairment Study

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the effect of severe RI on IHD on the PK of aleniglipron to establish scientifically guided dosing recommendations in these special patient populations.

Official title: A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Renal Impairment on Aleniglipron Pharmacokinetics

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2026-12

Completion Date

2027-03

Last Updated

2026-11-18

Healthy Volunteers

Yes

Interventions

DRUG

Aleniglipron

Administered orally

Locations (1)

Research Site

Orlando, Florida, United States